FDA Drug recall D-0871-2023
Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc
- FDA Drug
- Class III
- terminated
- Published 2023-06-21
On 2023-06-21 the FDA classified a Class III recall of Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc by Amring Pharmaceuticals, citing failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0871-2023 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2023-06-12 |
| Published | 2023-06-21 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Amring Pharmaceuticals |
| Distribution | US |
Product
Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc. Berwyn, PA 19312, NDC 69918-301-30
Reason
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Identifiers
| ndc | 69918-301-30 |
|---|---|
| code_info | Lots: X220317A and X220318A, exp. date 09/25 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0871-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.